Perspective: Evaluating Regulator Risk for Comparator Drug Products

| 01 May 2011 |  By 

Evaluating risks and developing mitigation strategies have become common industry practices in drug development. Regulatory agencies have adopted risk-based approaches in quality management, pharmaceutical development and postmarket surveillance of medicinal products.1-4

 

© 2022 Regulatory Affairs Professionals Society.

Discover more of what matters to you

No taxonomy